Related Experiment Video

Updated: Apr 17, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.9K

Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81

Jürgen Kuschyk1, Susanne Roeger1, Raphaela Schneider1

  • 1University Medical Centre, I. Medical Department, Mannheim, Germany.

International Journal of Cardiology
|February 10, 2015
PubMed

Insights

Cardiac contractility modulation (CCM) therapy significantly improved heart failure patient outcomes, including quality of life and exercise capacity. Long-term survival rates with CCM were observed to be lower than predicted by the MAGGIC score.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Chronic heart failure (CHF) poses a significant global health burden.
  • Current treatments for CHF have limitations in improving long-term outcomes and quality of life.

Purpose of the Study:

  • To evaluate the long-term efficacy and survival of patients with chronic heart failure receiving cardiac contractility modulation (CCM) therapy.
  • To compare observed mortality rates with predicted rates using the MAGGIC Score.

Main Methods:

  • Retrospective analysis of 81 patients implanted with a CCM device between 2004 and 2012.
  • Assessment of changes in NYHA class, ejection fraction (EF), quality of life (MLHFQ), NT-proBNP, and peak VO₂ over a mean follow-up of 34.2 months.
  • Comparison of observed mortality with MAGGIC Score predictions.

Main Results:

  • CCM therapy led to significant improvements in ejection fraction (EF) and NT-proBNP levels.
  • A 74.1% clinical responder rate was observed, with improvements in NYHA class and quality of life.
  • Observed mortality rates were significantly lower than predicted by the MAGGIC Score, particularly over 3 years of follow-up.

Conclusions:

  • Cardiac contractility modulation (CCM) therapy demonstrates long-term benefits in improving clinical status, exercise capacity, and quality of life in heart failure patients.
  • CCM therapy appears to reduce mortality in heart failure patients compared to risk stratification predictions.
Abstract

Keywords:
Cardiac contractility modulationDevice therapyHeart failure

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

15.7K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
582
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
611